89bio

ETNB52

$8.29arrow_drop_down0.24%-$0.02

ETNB52

$8.29

arrow_drop_down0.24%-$0.02

Performance History

Key Stats
Open	$8.49
Prev. Close	$8.35
EPS	-1.96
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-

PE Ratio	-

	LOW	HIGH
Day Range	8.10	8.62
52 Week Range	6.57	17.53

Ratios

Revenue	-



EBITDA Margin %	-

EPS	-1.96

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About 89bio (ETNB)

89bio Inc (ETNB) is a biopharmaceutical company focused on developing and commercializing innovative therapies for liver and cardio-metabolic diseases. The company's lead product candidate, BIO89-100, is a glycoPEGylated analog of fibroblast growth factor 21 (FGF21) for the treatment of NASH and severe hypertriglyceridemia. NASH, or nonalcoholic steatohepatitis, is a chronic liver disease characterized by fat accumulation, inflammation, and liver cell damage. Severe hypertriglyceridemia is a condition marked by high levels of triglycerides in the blood, which can increase the risk of cardiovascular disease.

89bio Inc's mission is to improve the lives of patients with liver and cardio-metabolic diseases through the development of novel therapies. The company's innovative approach is based on the modification of natural proteins to enhance their therapeutic potential. By optimizing the pharmacokinetic and pharmacodynamic properties of these proteins, 89bio Inc aims to provide more effective and convenient treatment options for patients.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Mr. Rohan Palekar
Headquarters: San Francisco
Employees: 45
Exchange: NASDAQ

Keep an eye on 89bio

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is 89bio 's (ETNB) price per share?

The current price per share for 89bio (ETNB) is $8.29. The stock has seen a price change of -$0.02 recently, indicating a -0.24% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for 89bio (ETNB)?

For 89bio (ETNB), the 52-week high is $17.33, which is 109.05% from the current price. The 52-week low is $6.58, the current price is 26.08% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is 89bio (ETNB) a growth stock?

89bio (ETNB) has shown an average price growth of 0.41% over the past three years. It has received a score of 95 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying 89bio as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is 89bio (ETNB) stock price performance year to date (YTD)?

As of the latest data, 89bio (ETNB) has a year-to-date price change of -26.57%. Over the past month, the stock has experienced a price change of -2.47%. Over the last three months, the change has been -1.31%. Over the past six months, the figure is -34.21%.

help

Is 89bio (ETNB) a profitable company?

89bio (ETNB) has a net income of -$142.19M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$151.2M. Furthermore, the EBITDA is -$191.22M.

help

What is the market capitalization of 89bio (ETNB)?

89bio (ETNB) has a market capitalization of $884.35M. The average daily trading volume is 449.89K, indicating the stock's liquidity and investor engagement.

News

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CHANGES IN COMPANY'S OWN SHARES

6/14/2024

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver Congress

89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver Congress

CHANGES IN COMPANY'S OWN SHARES

5/10/2024

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)